Dissemin is shutting down on January 1st, 2025

Published in

Springer Nature [academic journals on nature.com], British Journal of Cancer, 5(116), p. 649-657, 2017

DOI: 10.1038/bjc.2017.2

Links

Tools

Export citation

Search in Google Scholar

The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004).

Journal article published in 2017 by Ananya Choudhury, Catharine M. L. West, Nuria Porta, Emma Hall, Helen Denley, Carey Hendron, Rebecca Lewis, Syed A. Hussain ORCID, Robert Huddart, Nicholas James
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Severe chronic hypoxia is associated with tumour necrosis. In patients with muscle invasive bladder cancer (MIBC), necrosis is prognostic for survival following surgery or radiotherapy and predicts benefit from hypoxia modification of radiotherapy. Adding mitomycin C (MMC) and 5-fluorouracil (5-FU) chemotherapy to radiotherapy improved locoregional control (LRC) compared to radiotherapy alone in the BC2001 trial. We hypothesised that tumour necrosis would not predict benefit for the addition of MMC and 5-FU to radiotherapy, but would be prognostic.